- Home
- PPBT vs VRAX Comparison
PPBT vs VRAX Comparison
Compare PPBT & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPBT | VRAX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PPBT | VRAX |
|---|---|---|
| Price | $1.80 | $2.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $1.00 |
| AVG Volume (30 Days) | ★ 2.0M | 481.2K |
| Earning Date | 05-20-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.10 |
| 52 Week High | $5.18 | $13.19 |
Technical Indicators
Market Signals| Indicator | PPBT | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.